Glenmede Investment Management, LP Alkermes Plc. Transaction History
Glenmede Investment Management, LP
- $19.8 Trillion
- Q2 2025
A detailed history of Glenmede Investment Management, LP transactions in Alkermes Plc. stock. As of the latest transaction made, Glenmede Investment Management, LP holds 483,363 shares of ALKS stock, worth $15 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
483,363Holding current value
$15 Million% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding ALKS
# of Institutions
393Shares Held
176MCall Options Held
558KPut Options Held
427K-
Black Rock Inc. New York, NY29.1MShares$901 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA18.5MShares$573 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD10MShares$311 Million0.03% of portfolio
-
State Street Corp Boston, MA8.21MShares$254 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY6.41MShares$198 Million1.86% of portfolio
About Alkermes plc.
- Ticker ALKS
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 164,254,000
- Market Cap $5.08B
- Description
- Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ...